Phase I–II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma-Reference-Cited by-同舟云学术

Phase I–II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma

Published:2002-09 Issue:9 Volume:13 Page:1479-1489
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Faivre S.,Le Chevalier T.,Monnerat C.,Lokiec F.,Novello S.,Taieb J.,Pautier P.,Lhommé C.,Ruffié P.,Kayitalire L.,Armand J.-P.,Raymond E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/13/9/1479/415789/mdf219.pdf

Reference40 articles.

1. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis;Huang;Cancer Res,1991

2. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine);Hertel;Cancer Res,1990

3. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer;Abratt;J Clin Oncol,1997

5. Cisplatin–gemcitabine combination in advanced non-small-cell lung cancer: a phase II study;Crino;J Clin Oncol,1997

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin;European Thyroid Journal;2023-03-28

2. Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration;Current Issues in Molecular Biology;2021-12-07

3. Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring;Therapeutic Drug Monitoring;2017-06

4. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS;PLOS ONE;2017-02-13

5. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors;Investigational New Drugs;2016-11-21